King withdraws from Elan deal
King Pharmaceuticals, from Bristol, TN, US, has confirmed the Company does not plan to proceed with its acquisition of Elan Corporation's primary care business unit, which includes the products Sonata (zaleplon) and Skelaxin (metaxolone). King said its determination not to proceed with the acquisition resulted from various breaches and misrepresentations by Elan with respect to the Asset Purchase Agreement dated January 30 signed by King, Elan, and certain of their subsidiaries. Elan is suing to force King to close the transaction. A trial date of May 15 has been set by the judge in the Supreme Court of the State of New York.